Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Blood disorder, Chills, Dehydration, Dermatitis, Diarrhoea
Clinical narrative: body went into deep sepsis; pancreatitis; embolism in lung; dehydrated; dermatitis; blood disorder; Chills; fever; diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of SEPSIS (body went into deep sepsis), PANCREATITIS (pancreatitis), PULMONARY EMBOLISM (embolism in lung), CHILLS (Chills), PYREXIA (fever), DIARRHOEA (diarrhea), DEHYDRATION (dehydrated), DERMATITIS (dermatitis) and BLOOD DISORDER (blood disorder) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hashimoto's disease (Hashimoto's.). Concomitant products included ENALAPRIL for Blood pressure, ROSUVASTATIN, OMEPRAZOLE and LEVOTHYROXINE for an unknown indication.    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Jan-2021, the patient experienced CHILLS (Chills) (seriousness criterion hospitalization), PYREXIA (fever) (seriousness criterion hospitalization) and DIARRHOEA (diarrhea) (seriousness criterion hospitalization). On 26-Jan-2021, the patient experienced SEPSIS (body went into deep sepsis) (seriousness criteria hospitalization and medically significant), PANCREATITIS (pancreatitis) (seriousness criteria hospitalization and medically significant), PULMONARY EMBOLISM (embolism in lung) (seriousness criteria hospitalization and medically significant), DEHYDRATION (dehydrated) (seriousness criterion hospitalization), DERMATITIS (dermatitis) (seriousness criterion hospitalization) and BLOOD DISORDER (blood disorder) (seriousness criterion hospitalization). The patient was hospitalized from 26-Jan-2021 to 26-Feb-2021 due to BLOOD DISORDER, CHILLS, DEHYDRATION, DERMATITIS, DIARRHOEA, PANCREATITIS, PULMONARY EMBOLISM, PYREXIA and SEPSIS. The patient was treated with RIVAROXABAN (XARELTO) for Adverse event, at an unspecified dose and frequency; CARVEDILOL for Adverse event, at an unspecified dose and frequency and AMLODIPINE BESILATE (NORVASC) for Adverse event, at an unspecified dose and frequency. At the time of the report, SEPSIS (body went into deep sepsis), PANCREATITIS (pancreatitis), PULMONARY EMBOLISM (embolism in lung), CHILLS (Chills), PYREXIA (fever), DIARRHOEA (diarrhea), DEHYDRATION (dehydrated), DERMATITIS (dermatitis) and BLOOD DISORDER (blood disorder) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       On 22 Jan 2021, she started experiencing excessive chills, fever, diarrhea and chills again. she tried to fight off everything but became very dehydrated by 26 Jan 2021. So that day, 26 Jan 2021, she was admitted to the hospital she had to be in intensive care. The doctors told her that she went into a deep sepsis, had pancreatitis, embolism in lung, as well as dermatitis. She had a blood disorder due to which she started being seen by a Hem/Onc doctor. The patient was released from the hospital but re-admitted 2 more times due to these issues, with her final discharge date being 26 Feb 2021 from the hospital.  The patient had reported this to VAERS and was not sure if the hospital or her doctors ever reported it to Moderna. So she called to report everything to Moderna for awareness as she does not know what else to do. She also mentions that her doctors are very confident that her issues were caused by the Moderna vaccine and have told her to not receive another dose of it. Patient thought doctors may have increased her Levothyroxine dosage. The patient was treated with Eloquis.  Company Comment: This is a Spontaneous case concerning a 71-year-old female patient, with medical history of Hashimoto´s disease, who experienced the unexpected and serious events of Sepsis, Pancreatitis, Pulmonary embolism, Chills, Pyrexia, Diarrhoea, Dehydration, Dermatitis, and Blood disorder. Seriousness assessed due to hospitalization. The events of Chills, Pyrexia, and Diarrhoea, occurred 1 day after the first dose of mRNA-1273 vaccine; and 5 days later, the patient experienced Sepsis, Pancreatitis, Pulmonary embolism, Dehydration, Dermatitis, and Blood disorder. The medical history remains confounder. The benefit-risk relationship of mRNA- 1273 vaccine is not affected by this report.; Sender's Comments: This is a Spontaneous case concerning a 71-year-old female patient, with medical history of Hashimoto´s disease, who experienced the unexpected and serious events of Sepsis, Pancreatitis, Pulmonary embolism, Chills, Pyrexia, Diarrhoea, Dehydration, Dermatitis, and Blood disorder. Seriousness assessed due to hospitalization. The events of Chills, Pyrexia, and Diarrhoea, occurred 1 day after the first dose of mRNA-1273 vaccine; and 5 days later, the patient experienced Sepsis, Pancreatitis, Pulmonary embolism, Dehydration, Dermatitis, and Blood disorder. The medical history remains confounder. The benefit-risk relationship of mRNA- 1273 vaccine is not affected by this report.